Publications by authors named "Colleen Marano"

Claim this Profile
C
Clinical Trial: Association Between Early Disease Clearance and Long-Term Outcomes-4-Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis.
Silvio Danese, Rupert W Leong, Bruce E Sands, Tony Ma, Colleen Marano

Aliment Pharmacol Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis.
Subrata Ghosh, Brian G Feagan, Elyssa Ott, Christopher Gasink, Bridget Godwin, Colleen Marano

J Crohns Colitis· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study.
Waqqas Afif, Ramesh P Arasaradnam, Maria T Abreu, Silvio Danese, William J Sandborn, Colleen Marano

Am J Gastroenterol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial.
Silvio Danese, Bruce E Sands, Maria T Abreu, Christopher D O'Brien, Ivana Bravatà, Colleen Marano

Clin Gastroenterol Hepatol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension.
Maria T Abreu, David S Rowbotham, Silvio Danese, William J Sandborn, Ye Miao, Colleen Marano

J Crohns Colitis· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI).
Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, Yasuo Suzuki, Yoshifumi Ohnishi, Colleen W Marano

Intest Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies.
William J Sandborn, Brian G Feagan, Silvio Danese, Christopher D O'Brien, Elyssa Ott, Colleen Marano

Inflamm Bowel Dis· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments.
Klaus Gottlieb, Marco Daperno, Keith Usiskin, Bruce E Sands, Harris Ahmad, Colleen Marano

Gut· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis.
Katherine Li, Colleen Marano, Hongyan Zhang, Feifei Yang, William J Sandborn

Gastroenterology· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
Remo Panaccione, Silvio Danese, William J Sandborn, Christopher D O'Brien, Yiying Zhou, Colleen Marano

Aliment Pharmacol Ther· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis.
Omoniyi J Adedokun, Zhenhua Xu, Colleen Marano, Chris O'Brien, Philippe Szapary

Clin Gastroenterol Hepatol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. Reply.
Bruce E Sands, Colleen Marano

N Engl J Med· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opioid Use in Patients With Inflammatory Bowel Disease.
Xiwu Lin, Jennifer Lofland, Ling Zhang, Sheldon Sloan, Laila Chamaa, Colleen Marano

Crohns Colitis 360· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data.
George Philip, Freddy Cornillie, J Omoniyi Adedokun, Richard Melsheimer, Paul Rutgeerts, Colleen Marano

J Crohns Colitis· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Bruce E Sands, William J Sandborn, Remo Panaccione, Christopher D O'Brien, Hongyan Zhang, Colleen Marano

N Engl J Med· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Simplified Definition of Histologic Improvement in Ulcerative Colitis and its Association With Disease Outcomes up to 30 Weeks from Initiation of Therapy: Post Hoc Analysis of Three Clinical Trials.
Katherine Li, Richard Strauss, Colleen Marano, Linda E Greenbaum, Joshua R Friedman

J Crohns Colitis· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab.
Walter Reinisch, Jean-Frederic Colombel, Peter R Gibson, Paul Rutgeerts, William J Sandborn, Colleen Marano

Inflamm Bowel Dis· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study.
Bruce E Sands, William J Sandborn, Brian G Feagan, Gary R Lichtenstein, Hongyan Zhang, Colleen Marano

J Crohns Colitis· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension.
Walter Reinisch, Peter R Gibson, William J Sandborn, Brian G Feagan, Richard Strauss, Colleen Marano

J Crohns Colitis· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
Omoniyi J Adedokun, Zhenhua Xu, Colleen W Marano, Richard Strauss, Hongyan Zhang

J Crohns Colitis· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year.
Peter R Gibson, Brian G Feagan, William J Sandborn, Colleen Marano, Richard Strauss

Clin Transl Gastroenterol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.
Ian Landells, Colleen Marano, Ming-Chun Hsu, Shu Li, Yaowei Zhu

J Am Acad Dermatol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
Omoniyi J Adedokun, William J Sandborn, Brian G Feagan, Paul Rutgeerts, Zhenhua Xu, Colleen W Marano

Gastroenterology· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
William J Sandborn, Brian G Feagan, Colleen Marano, Hongyan Zhang, Richard Strauss

Gastroenterology· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
William J Sandborn, Brian G Feagan, Colleen Marano, Hongyan Zhang, Richard Strauss

Gastroenterology· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis